![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Utuly (epinephrine) is a nonselective alpha- and beta-adrenergic receptor agonist. Through its action on alpha-adrenergic receptors, it reduces vasodilation and increases vascular permeability that occurs during anaphylaxis.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: Utuly
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 24, 2023
Details:
Utuly, an epinephrine nasal spray, for the treatment of anaphylaxis. It is designed to provide patients with a life-saving treatment that is needle free, fits in a pocket, is easy to use, and complies with practice parameters.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: Utuly
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 13, 2022
Details:
Proceeds from the financing will be used to fund the remaining development and regulatory approval activities, and pre-launch commercialization program for BRYN-NDS1C, Bryn's bi-dose epinephrine nasal spray.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: BRYN-NDS1C
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $26.0 million Upfront Cash: Undisclosed
Deal Type: Financing August 04, 2020
Details:
The preclinical results described in the publications were used to support the advancement of BRYN-NDS1C into the human clinical trial program currently underway.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 10, 2020
Details:
Intranasal (IN) delivery of epinephrine from Bryn's needle-free Bi-dose Epinephrine Nasal Spray was comparable to intramuscular (IM) injection in pharmacokinetics, pharmacodynamics, and safety.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 06, 2020